Irvine, D. J., Maus, M. V., Mooney, D. J. & Wong, W. W. The future of engineered immune cell therapies. Science 378, 853–858 (2022).
Article CAS PubMed PubMed Central Google Scholar
Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625–638 (2019).
Article CAS PubMed Google Scholar
Lu, H., Zhao, X., Li, Z., Hu, Y. & Wang, H. From CAR-T cells to CAR-NK cells: a developing immunotherapy method for hematological malignancies. Front. Oncol. 11, 720501 (2021).
Article CAS PubMed PubMed Central Google Scholar
Schmidt, P., Raftery, M. J. & Pecher, G. Engineering NK Cells for CAR therapy-recent advances in gene transfer methodology. Front. Immunol. 11, 611163 (2020).
Article CAS PubMed Google Scholar
Berrien-Elliott, M. M., Jacobs, M. T. & Fehniger, T. A. Allogeneic natural killer cell therapy. Blood 141, 856–868 (2023).
Article CAS PubMed Google Scholar
Coyle, K. M., Hawke, L. G. & Ormiston, M. L. Addressing natural killer cell dysfunction and plasticity in cell-based cancer therapeutics. Cancers 15, 1743 (2023).
Article CAS PubMed PubMed Central Google Scholar
Laskowski, T. J., Biederstädt, A. & Rezvani, K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat. Rev. Cancer 22, 557–575 (2022).
Article CAS PubMed PubMed Central Google Scholar
Ramírez-Labrada, A. et al. All About (NK cell-mediated) death in two acts and an unexpected encore: initiation, execution and activation of adaptive immunity. Front. Immunol. 13, 896228 (2022).
Article PubMed PubMed Central Google Scholar
Böttcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022–1037 (2018).
Article PubMed PubMed Central Google Scholar
Huntington, N. D., Cursons, J. & Rautela, J. The cancer-natural killer cell immunity cycle. Nat. Rev. Cancer 20, 437–454 (2020).
Article CAS PubMed Google Scholar
Pai, J. A. et al. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. Cancer Cell 41, 776–790 (2023).
Article CAS PubMed PubMed Central Google Scholar
Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).
Oh, D. Y. et al. Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 181, 1612–1625(2020).
Article CAS PubMed PubMed Central Google Scholar
Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015).
Article CAS PubMed PubMed Central Google Scholar
Cherkassky, L. et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126, 3130–3144 (2016).
Article PubMed PubMed Central Google Scholar
Steele, M. M. et al. T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control. Nat. Immunol. 24, 664–675 (2023). This study unveils the CXCR4–CXCL12 axis as an important target for enhancing intratumoral T cell retention in vivo.
Article CAS PubMed Google Scholar
Thacker, G. et al. Immature natural killer cells promote progression of triple-negative breast cancer. Sci. Transl. Med. 15, eabl4414 (2023). This study uncovers a ‘regulatory-like’ immature NK cell population that could be targeted to improve efficacy of immunotherapies against triple-negative breast cancer.
Nuñez, S. Y. et al. Human M2 macrophages limit NK cell effector functions through secretion of TGF-β and engagement of CD85j. J. Immunol. 200, 1008–1015 (2018).
Kloosterman, D. J. & Akkari, L. Macrophages at the interface of the co-evolving cancer ecosystem. Cell 186, 1627–1651 (2023).
Article CAS PubMed Google Scholar
Reinfeld, B. I. et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593, 282–288 (2021).
Article CAS PubMed PubMed Central Google Scholar
Zalfa, C. & Paust, S. Natural killer cell interactions with myeloid derived suppressor cells in the tumor microenvironment and implications for cancer immunotherapy. Front. Immunol. 12, 633205 (2021).
Article CAS PubMed PubMed Central Google Scholar
Eschweiler, S. et al. Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy. Nat. Immunol. 22, 1052–1063 (2021).
Article CAS PubMed PubMed Central Google Scholar
Maalej, K. M. et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol. Cancer 22, 20 (2023).
Article CAS PubMed PubMed Central Google Scholar
Tai, L. H., Zhang, J. & Auer, R. C. Preventing surgery-induced NK cell dysfunction and cancer metastases with influenza vaccination. Oncoimmunology 2, e26618 (2013).
Article PubMed PubMed Central Google Scholar
Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545–553 (2020).
Article CAS PubMed PubMed Central Google Scholar
Xiao, X. et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J. Exp. Clin. Cancer Res. 40, 367 (2021).
Article CAS PubMed PubMed Central Google Scholar
Zhang, X. et al. Cytokine release syndrome after modified CAR-NK therapy in an advanced non-small cell lung cancer patient: a case report. Cell Transplant. 31, 9636897221094244 (2022).
Klingemann, H. Are natural killer cells superior CAR drivers? Oncoimmunology 3, e28147 (2014).
Article PubMed PubMed Central Google Scholar
Paul, S. & Lal, G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front. Immunol. 8, 1124 (2017).
Article PubMed PubMed Central Google Scholar
Whang, M. et al. Large-scale expansion and engineering of human NK cells sourced from peripheral blood versus umbilical cord blood. J. Immunother. Cancer 10, A401 (2022).
Min, B. et al. Optimization of large-scale expansion and cryopreservation of human natural killer cells for anti-tumor therapy. Immune Netw. 18, e31 (2018).
Article PubMed PubMed Central Google Scholar
Davenport, A. J. et al. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc. Natl Acad. Sci. USA 115, E2068–E2076 (2018). This study identifies an immature immunological synapse formed by CAR molecules in CAR-T cells as compared to canonical TCR.
Article CAS PubMed PubMed Central Google Scholar
Monks, C. R., Freiberg, B. A., Kupfer, H., Sciaky, N. & Kupfer, A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395, 82–86 (1998).
Article CAS PubMed Google Scholar
Watanabe, K., Kuramitsu, S., Posey, A. D. Jr. & June, C. H. Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology. Front. Immunol. 9, 2486 (2018).
Article PubMed PubMed Central Google Scholar
Al-Aghbar, M. A., Jainarayanan, A. K., Dustin, M. L. & Roffler, S. R. The interplay between membrane topology and mechanical forces in regulating T cell receptor activity. Commun. Biol. 5, 40 (2022).
Article CAS PubMed PubMed Central Google Scholar
Somersalo, K. et al. Cytotoxic T lymphocytes form an antigen-independent ring junction. J. Clin. Invest. 113, 49–57 (2004).
Article CAS PubMed PubMed Central Google Scholar
Potter, T. A., Grebe, K., Freiberg, B. & Kupfer, A. Formation of supramolecular activation clusters on fresh ex vivo CD8+ T cells after engagement of the T cell antigen receptor and CD8 by antigen-presenting cells. Proc. Natl Acad. Sci. USA 98, 12624–12629 (2001).
留言 (0)